Feedback
Settings

Settings

Goto Application

660,643 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 66,065
1.20250361547DIAGNOSTIC MICROPARTICLE PROBE COMPRISING MAGNETIC PARTICLE AND INACTIVATED GENETIC SCISSORS, AND MULTI-DIAGNOSTIC SYSTEM AND METHOD INVOLVING PROBE
US - 27.11.2025
Int.Class C12Q 1/6825
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6816characterised by the detection means
6825Nucleic acid detection involving sensors
 Appl.No 18874143 Applicant EZDIATECH INC. Inventor Yong-Gyun JUNG

The present invention relates to a diagnostic microparticle probe comprising a magnetic particle and an inactivated genetic scissors, and a multi-diagnostic system and multi-diagnostic method comprising the same, which may not only perform a rapid and accurate diagnosis compared to conventional diagnostic methods but also may be used for multiple diagnoses, by introducing genetic scissors technology into a diagnostic microparticle probe.

2.20250361551MODIFIED PRIMERS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION
US - 27.11.2025
Int.Class C12Q 1/6853
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
6853using modified primers or templates
 Appl.No 19178452 Applicant Binx Health Limited Inventor Daniel Adlerstein

A method of nucleic acid amplification involving using a first modified primer which provides protection to the amplification product from exonuclease degradation and a second primer. The method provides a double stranded nucleic acid, one strand of which is degraded by a double strand nucleic acid specific exonuclease to form a single stranded nucleic acid, which is protected from exonuclease degradation.

3.20250360508SORTING A DROPLET INCLUDING A BIOLOGIC SAMPLE
US - 27.11.2025
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
 Appl.No 19289730 Applicant Hewlett-Packard Development Company, L.P. Inventor Alexander Govyadinov

Examples herein involve sorting a droplet including a biologic sample. In a particular example, sorting a droplet including a biologic sample includes generating a droplet including a biologic sample and a pH sensitive surfactant, and heating a nucleic acid molecule in the biologic sample. The pH sensitive surfactant may change the surface tension of the droplet responsive to amplification of the nucleic acid molecule. The droplet may be sorted into one of a plurality of sorting lanes based on the surface tension of the droplet, where a sorting lane among the plurality of sorting lanes is associated with droplets including the amplified nucleic acid molecule. A determination of whether the droplet includes the amplified nucleic acid molecule may be performed by detecting passage of the droplet in one of the plurality of sorting lanes.

4.WO/2025/241021IN VITRO METHOD, BIOMARKER PANEL, KIT FOR PREDICTION, SCREENING, MONITORING AND/OR DIAGNOSIS OF DIABETIC KIDNEY DISEASE AND METHOD OF TREATMENT
WO - 27.11.2025
Int.Class C12Q 1/6876
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
 Appl.No PCT/BR2025/050193 Applicant LIQSCI BIOTECNOLOGIA LTDA Inventor REIS, Beatriz Da Costa Aguiar Alves
The present invention pertains to the fields of molecular biology and medicine. More specifically, the present invention discloses the use of TNFR1 as a biomarker for predicting, screening, monitoring and/or diagnosing diabetic kidney disease in mammals. A kit and a biomarker panel comprising two or more genes selected from among the following are disclosed: TNFR1, MCT1, MCT4, CD147, HIF-1α and VEGFα, SMAD1 and NGAL. An in vitro method for predicting, screening, monitoring and/or diagnosing diabetic kidney disease is also disclosed, comprising quantifying the gene expression of TNFR1, MCT1, MCT4, CD147, HIF-1α, VEGFA, SMAD1 and/or NGAL and comparing it with the level of a control sample. The present invention provides a new and improved strategy for tracking early renal changes resulting from the progression of diabetes mellitus.
5.WO/2025/243496METHOD FOR CREATING MASS SPECTRUM DATABASE, METHOD FOR EVALUATING MASS SPECTRUM QUALITY, METHOD FOR DISTINGUISHING MICROORGANISM, AND ANALYSIS DEVICE FOR CREATING MASS SPECTRUM DATABASE
WO - 27.11.2025
Int.Class G01N 27/62
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
62by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
 Appl.No PCT/JP2024/019160 Applicant SHIMADZU CORPORATION Inventor OKUBO, Tatsuki
This method comprises: a step for acquiring one or more mass spectra obtained by performing mass analysis of an analysis specimen prepared from a microorganism specimen including a microorganism, and creating collected data including the acquired mass spectra; a step for evaluating whether the mass spectra included in the collected data satisfy a quality standard determined in advance; and a step for creating a mass spectrum database using the mass spectra which satisfy the quality standard. The step for evaluating whether the quality standard is satisfied includes, for each mass spectrum: a step for calculating a first integrated value of the peak intensity of a peak included in a first m/z range corresponding to a contaminant in the analysis sample; a step for calculating a second integrated value of the peak intensity of a peak included in a second m/z region differing from the first m/z region; and a step for evaluating whether the ratio of the first integrated value to the second integrated value satisfies a specified condition.
6.WO/2025/245131TUMOR MARKER SELECTION AND DETECTION
WO - 27.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2025/030223 Applicant SAGA DX, INC. Inventor ALCAIDE, Miguel
Methods for detecting a tumor using a sample in which tumor DNA fragments are present only in a very low concentration, beyond the statistical limit of detection, where methods include: obtaining sequence data for tumor nucleic acid from a tumor from a subject and analyzing the sequence data to identify a plurality of tumor-specific variants that are in the tumor nucleic acid and that are not in non-tumor nucleic acid of the subject; selecting a marker variant that appears duplicated in tumor nucleic acid (compared to non-tumor nucleic acid) a greater number of times than other ones of the tumor variants; performing an assay to detect the marker variant in a sample from the subject; and reporting the presence of the tumor in the subject when the assay is positive for the marker variant in the sample.
7.WO/2025/242806A METHOD FOR PREDICTING THE RESPONSE OF A PATIENT WITH DLBCL TO ANTI-IL-1ß THERAPY
WO - 27.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2025/064145 Applicant UNIVERSITÄT DUISBURG-ESSEN Inventor KNITTEL, Gero
The present invention relates to a method for predicting a response of a patient with diffuse large B-cell lymphoma (DLBCL) to anti-IL-1β therapy. This comprises detecting a mutation in the IRF2BP2 gene and/or a lack of IRF2BP2 protein expression of the patient's DLBCL cells in a sample derived from the patient. In addition, the invention relates to the use of such detection for predicting a response of the patient to IL-1β therapy and a corresponding PCR kit.
8.WO/2025/245056GASTRIC CANCER RNA BIOMARKERS AND USES THEREOF
WO - 27.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2025/030114 Applicant CITY OF HOPE Inventor GOEL, Ajay
Methods of diagnosing, monitoring, or treating gastric cancer (e.g., early gastric cancer) in a patient are accomplished by detecting the expression levels of RNA biomarkers (e.g., microRNA biomarkers) in a biological sample. Such RNA biomarkers include, for example, miR-21-3p, miR-21-5p, miR-215-5p, miR-335-3p, miR-27a-3p, miR-95-3p, miR-181b-5p, miR- 431-5p, miR-1246. miR-192-3p. miR-196a-5p, miR-183-5p, and miR-135b-5p. The RNA biomarkers can be cell-free miRNA, exosomal miRNA, or a combination thereof, such as cell-free miR-21-3p, cell-free miR-21-5p, cell-free miR-215-5p, cell-free miR-335-3p, cell-free miR- 27a-3p, cell-free miR-95-3p, cell-free miR-181b-5p, cell-free miR-431-5p, exosomal miR-21- 3p, exosomal miR-21-5p, exosomal miR-1246, exosomal miR-192-3p, exosomal miR-215-5p, exosomal miR-27a-3p, exosomal miR-95-3p, exosomal miR-196a-5p, exosomal miR-183-5p, and exosomal miR-135b-5p.
9.WO/2025/244441METHOD FOR SCREENING THERAPEUTIC AGENT FOR DEMYELINATION-RELATED DISEASES
WO - 27.11.2025
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No PCT/KR2025/006978 Applicant ENCELL CO., LTD. Inventor CHANG, Jong Wook
The present invention relates to a method for screening a therapeutic agent for demyelination-related diseases by performing a first screening and a second screening, wherein the first screening comprises the steps of: (1-1) treating Schwann cells with a candidate material; and (1-2) measuring a proliferation index level of Schwann cells in cells treated with the candidate material, and the second screening comprises the steps of: (2-1) inducing demyelination in Schwann cells; (2-2) treating the demyelinated Schwann cells with a candidate material; and (2-3) measuring the level of a Schwann cell proliferation index, a myelination index, or both in the cells treated with the candidate material.
10.20250361549DETECTION OF EPIGENETIC CYTOSINE MODIFICATION
US - 27.11.2025
Int.Class C12Q 1/6827
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
 Appl.No 18873630 Applicant Roche Sequencing Solutions, Inc. Inventor Dieter Heindl

The invention includes improved methods and compositions for reduction of a C5-C6 double bond of a cytosine. In particular, the improved methods and compositions for reduction of a C5-C6 double bond of a cytosine is via enzymatic means, not via chemical means. In particular, the disclosure is directed to methods of converting 5,6-dihydro-fC (fC) and/or 5,6-dihydro-caC to 5,6-dihydro-U (DHU). In particular, the disclosure is directed to methods of converting 5fC and/or 5caC to DHU. In addition, the disclosure is directed to methods for detection of epigenetic cytosine modification, particularly cytosine methylation, using ene reductases to reduce the C5-C6 double bond of cytosine.

# -